SarinSK,KumarM,LauGK,AbbasZ,ChanHL,ChenCJ, 2016.Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update,Hepatol Int 10 1 -98
LiawYF,SungJJ,ChowWC,FarrellG,LeeCZ,YuenH, 2004.Lamivudine for patients with chronic hepatitis B and advanced liver disease,N Engl J Med 351 1521 -31
ChangTT,LaiCL,Kew YoonS,LeeSS,CoelhoHS,CarrilhoFJ, 2010.Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B,Hepatology 51 422 -30
HosakaT,SuzukiF,KobayashiM,SekoY,KawamuraY,SezakiH, 2013.Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection,Hepatology 58 98 -107
-, 2015.Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection (, -
HiramatsuN,YamadaR,TakeharaT., 2016.The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients,J Gastroenterol Hepatol 31 546 -52
KobashiH,MiyakeY,IkedaF,YasunakaT,NishinoK,MoriyaA, 2011.Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine,Hepatol Res 41 405 -16
LimYS,HanS,HeoNY,ShimJH,LeeHC,SuhDJ, 2014.Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine,Gastroenterology 147 152 -61
KimSS,HwangJC,LimSG,AhnSJ,CheongJY,ChoSW, 2014.Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: Comparison between compensated and decompensated cirrhosis,Am J Gastroenterol 109 1223 -33
AltmanDG,AndersenPK, 1999.Calculating the number needed to treat for trials where the outcome is time to an event,BMJ 319 1492 -5
LoKJ,TongMJ,ChienMC,TsaiYT,LiawYF,YangKC, 1982.The natural course of hepatitis B surface antigen-positive chronic active hepatitis in Taiwan,J Infect Dis 146 205 -10
KatoY,NakataK,OmagariK,FurukawaR,KusumotoY,MoriI, 1994.Risk of hepatocellular carcinoma in patients with cirrhosis in Japan,Cancer 74 2234 -8
PapatheodoridisGV,LamperticoP,ManolakopoulosS,LokA, 2010.Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review,J Hepatol 53 348 -56
TawadaA,KandaT,ImazekiF,YokosukaO, 2016.Prevention of hepatitis B virus-associated liver diseases by antiviral therapy,Hepatol Int 10 574 -93
BiJ,ZhangZ,QinE,HouJ,LiuS,LiuZ, 2017.Nucleoside analogs treatment delay the onset of hepatocellular carcinoma in patients with HBV-related cirrhosis,Oncotarget 8 96725 -31
ZoutendijkR,ReijndersJG,ZoulimF,BrownA,MutimerDJ,DeterdingK, 2013.Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis,Gut 62 760 -5
GordonSC,LameratoLE,RuppLB,LiJ,HolmbergSD,MoormanAC, 2014.Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population,Clin Gastroenterol Hepatol 12 885 -93
ArendsP,SonneveldMJ,ZoutendijkR,CareyI,BrownA,FasanoM, 2015.Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: Limited role for risk scores in Caucasians,Gut 64 1289 -95
RaptiI,Hadziyannis S, 2015.Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues,World J Hepatol 7 1064 -73
PapatheodoridisGV,IdilmanR,DalekosGN,ButiM,ChiH,van BoemmelF, 2017.The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B,Hepatology 66 1444 -53
ChangTT,GishRG,de ManR,GadanoA,SollanoJ,ChaoYC, 2006.A comparison of entecavir and lamivudine for HBeAgpositive chronic hepatitis B,N Engl J Med 354 1001 -10
YuJH,LeeJI, 2017.Current role of transient elastography in the management of chronic hepatitis B patients,Ultrasonography 36 86 -94
ChenCF,LeeWC,YangHI,ChangHC,JenCL,IloejeUH, 2011.Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma,Gastroenterology 141 1240 -8
NamJY,ChangY,ChoH,KangSH,ChoYY,ChoEJ, 2018.Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B,J Viral Hepat 25 552 -60
KurokawaM,HiramatsuN,OzeT,YakushijinT,MiyazakiM,HosuiA, 2012.Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection,J Gastroenterol 47 577 -85